| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies BD Lehmann, JA Bauer, X Chen, ME Sanders, AB Chakravarthy, Y Shyr, ... The Journal of clinical investigation 121 (7), 2750-2767, 2011 | 5313 | 2011 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2461 | 2012 |
| Increase in Circulating Products of Lipid Peroxidation (F2-Isoprostanes) in Smokers — Smoking as a Cause of Oxidative Damage JD Morrow, B Frei, AW Longmire, JM Gaziano, SM Lynch, Y Shyr, ... New England Journal of Medicine 332 (18), 1198-1203, 1995 | 1762 | 1995 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1653 | 2014 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1647 | 2020 |
| Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis L Yang, LM DeBusk, K Fukuda, B Fingleton, B Green-Jarvis, Y Shyr, ... Cancer cell 6 (4), 409-421, 2004 | 1278 | 2004 |
| Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ... PloS one 11 (6), e0157368, 2016 | 1099 | 2016 |
| Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation E Montgomery, MP Bronner, JR Goldblum, JK Greenson, MM Haber, ... Human pathology 32 (4), 368-378, 2001 | 997 | 2001 |
| Proteomic patterns of tumour subsets in non-small-cell lung cancer K Yanagisawa, Y Shyr, BJ Xu, PP Massion, PH Larsen, BC White, ... The Lancet 362 (9382), 433-439, 2003 | 798 | 2003 |
| Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention H Mertz, V Morgan, G Tanner, D Pickens, R Price, Y Shyr, R Kessler Gastroenterology 118 (5), 842-848, 2000 | 760 | 2000 |
| The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor AE Powell, Y Wang, Y Li, EJ Poulin, AL Means, MK Washington, ... Cell 149 (1), 146-158, 2012 | 711 | 2012 |
| Nationwide trends in mastectomy for early-stage breast cancer KL Kummerow, L Du, DF Penson, Y Shyr, MA Hooks JAMA surgery 150 (1), 9-16, 2015 | 643 | 2015 |
| Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer JJ Smith, NG Deane, F Wu, NB Merchant, B Zhang, A Jiang, P Lu, ... Gastroenterology 138 (3), 958-968, 2010 | 633 | 2010 |
| Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer TW Miller, BT Hennessy, AM González-Angulo, EM Fox, GB Mills, H Chen, ... The Journal of clinical investigation 120 (7), 2406-2413, 2010 | 573 | 2010 |
| Plasma cytokine levels predict mortality in patients with acute renal failure EM Simmons, J Himmelfarb, MT Sezer, GM Chertow, RL Mehta, ... Kidney international 65 (4), 1357-1365, 2004 | 545 | 2004 |
| Reamed intramedullary nailing of the femur: 551 cases PR Wolinsky, E McCarty, Y Shyr, K Johnson Journal of Trauma and Acute Care Surgery 46 (3), 392-399, 1999 | 496 | 1999 |
| Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study TA Ikizler, RL Wingard, J Harvell, Y Shyr, RM Hakim Kidney international 55 (5), 1945-1951, 1999 | 478 | 1999 |
| Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ R Chinery, JA Brockman, MO Peeler, Y Shyr, RD Beauchamp, RJ Coffey Nature medicine 3 (11), 1233-1241, 1997 | 472 | 1997 |
| DC isoketal-modified proteins activate T cells and promote hypertension A Kirabo, V Fontana, APC De Faria, R Loperena, CL Galindo, J Wu, ... The Journal of clinical investigation 124 (10), 4642-4656, 2014 | 460 | 2014 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 435 | 2016 |
